1. Scrip
  2. >>Business

Profile: MSD India Chief On DEI Values, Keytruda And 'Drinking From The Firehose'

 
• By Anju Ghangurde

MSD India managing director Rehan Khan shares with Scrip glimpses of his life and professional journey, including diversity, equity and inclusion values imbibed in his childhood, co-founding an early-stage venture fund, widening access to Keytruda to roughly “six times more patients” in the country and initiatives around HPV vaccination.

Rehan Khan, Managing Director, MSD India • Source: MSD India

Ensuring patient access and diversity, equity and inclusion (DEI) may be at the core of pharma’s current corporate policies, but MSD India managing director Rehan Khan was exposed to those values way back in his younger days.

Khan, who was born in the UK but spent part of his childhood in Aligarh and in Mussoorie, India, recounts...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Alkermes To Buy Avadel, Jumpstarting A Move Into Commercial Sleep Market

 
• By Jessica Merrill

The company will gain Lumryz, an oxybate for narcolepsy, paving the commercial path ahead of the eventual launch of its own Phase III-ready asset alixorexton.

Alector Moves On To Alzheimer’s Drug After Latozinemab Flunks Phase III

 
• By Alaric DeArment

The company said the INFRONT-3 trial in FTN-GRN failed to meet a co-primary endpoint and secondary endpoints. Alector is cutting 49% of its staff to conserve cash.

Deal Watch: AstraZeneca Remains Busy In AI, Via Deals With Immunai, Turbine And Algen

 
• By Joseph Haas and Lisa Takagi

Plus deals involving Takeda/Innovent, Genentech/Ventus, Sanofi/EVOQ, Novo Nordisk/Sumitomo, Lisata/Catalent, Boehringer Ingelheim/Accent, BI/Molcure, tech transfer agreements and more.

Ipsen Boosts Cancer Pipeline With ImCheck Buy

 
• By Kevin Grogan

The Paris-based group is paying €350m upfront to get hold of Marseille-headquartered ImCheck's acute myeloid leukemia candidate.

More from Scrip

Ipsen Boosts Cancer Pipeline With ImCheck Buy

 
• By Kevin Grogan

The Paris-based group is paying €350m upfront to get hold of Marseille-headquartered ImCheck's acute myeloid leukemia candidate.

Sanofi’s Inhibrx-Acquired Rare Disease Therapy Clears Phase II Hurdle

 
• By Manas Mishra

Efdoralprin alfa, which was acquired through Inhibrx, has met the endpoints of a Phase II trial for alpha-1 antitrypsin deficiency.

Sponsored by :

Podcast: Innovating Autoimmune Treatment with In Vivo CAR-T

As in vivo CAR-T therapy nears clinical use, researchers and industry leaders explore how it could transform autoimmune disease treatment. Novotech’s Pete Robinson joins Citeline’s Meredith Landry to discuss the science, strategy, and partnerships shaping the future of cell therapy.